FDA Provides Draft Guidance on Early Lyme Disease Drug Development
March 31, 2023
A new FDA draft guidance for sponsors developing drugs to treat early Lyme disease focuses on trial designs for treatment of erythema migrans, a rash that often appears as one of the first symptoms in the disease’s early stages.